Multimodal treatment of colorectal liver metastases: Where are we? Current strategies and future perspectives.

IF 5.7 4区 生物学 Q1 BIOLOGY
Caterina Accardo, Ivan Vella, Fabrizio di Francesco, Sergio Rizzo, Sergio Calamia, Alessandro Tropea, Pasquale Bonsignore, Sergio Li Petri, Salvatore Gruttadauria
{"title":"Multimodal treatment of colorectal liver metastases: Where are we? Current strategies and future perspectives.","authors":"Caterina Accardo, Ivan Vella, Fabrizio di Francesco, Sergio Rizzo, Sergio Calamia, Alessandro Tropea, Pasquale Bonsignore, Sergio Li Petri, Salvatore Gruttadauria","doi":"10.5582/bst.2025.01012","DOIUrl":null,"url":null,"abstract":"<p><p>Despite the continued high prevalence of colorectal cancer in the Western world, recent years have witnessed a decline in its mortality rate, largely attributable to the sustained advancement of multimodal treatment modalities for metastatic patients. One persisting issue is lack of consensus between different centres and multidisciplinary teams regarding definition of resectability, the duration of chemotherapy treatment, and surgical strategy. This narrative review outlines current multimodal treatment of patients with colon cancer metastatic to the liver and/or lung in different clinical scenarios. Currently, there are multiple multimodal strategies that can be employed to enhance resectability in these patients. These include novel and sophisticated target therapies (such as novel immunotherapeutic modalities and micro RNAs), complex resections utilising parenchyma-sparing techniques, liver transplantation, and cytoreductive strategies in patients for whom a curative option is not feasible. It is the responsibility of the scientific community to establish standardised protocols across different centres, based on the most recent evidence, while maintaining a high degree of personalisation of treatment for each individual patient. It seems likely that artificial intelligence (AI) will play a significant role in achieving this goal.</p>","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioscience trends","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.5582/bst.2025.01012","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Despite the continued high prevalence of colorectal cancer in the Western world, recent years have witnessed a decline in its mortality rate, largely attributable to the sustained advancement of multimodal treatment modalities for metastatic patients. One persisting issue is lack of consensus between different centres and multidisciplinary teams regarding definition of resectability, the duration of chemotherapy treatment, and surgical strategy. This narrative review outlines current multimodal treatment of patients with colon cancer metastatic to the liver and/or lung in different clinical scenarios. Currently, there are multiple multimodal strategies that can be employed to enhance resectability in these patients. These include novel and sophisticated target therapies (such as novel immunotherapeutic modalities and micro RNAs), complex resections utilising parenchyma-sparing techniques, liver transplantation, and cytoreductive strategies in patients for whom a curative option is not feasible. It is the responsibility of the scientific community to establish standardised protocols across different centres, based on the most recent evidence, while maintaining a high degree of personalisation of treatment for each individual patient. It seems likely that artificial intelligence (AI) will play a significant role in achieving this goal.

多模式治疗结直肠癌肝转移:进展如何?当前战略和未来展望。
尽管结直肠癌在西方世界的发病率仍然很高,但近年来其死亡率有所下降,这主要归功于对转移性患者的多模式治疗方式的持续进步。一个持续存在的问题是不同的中心和多学科团队对可切除性的定义、化疗的持续时间和手术策略缺乏共识。这篇叙述性综述概述了目前在不同临床情况下结肠癌转移到肝脏和/或肺的多模式治疗。目前,有多种多模式策略可用于提高这些患者的可切除性。这些包括新颖和复杂的靶向治疗(如新的免疫治疗模式和微rna),利用保留实质技术的复杂切除,肝移植和治疗方案不可行的患者的细胞减少策略。科学界有责任根据最新的证据,在不同的中心建立标准化的方案,同时为每个患者保持高度的个性化治疗。似乎人工智能(AI)将在实现这一目标方面发挥重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
13.60
自引率
1.80%
发文量
47
审稿时长
>12 weeks
期刊介绍: BioScience Trends (Print ISSN 1881-7815, Online ISSN 1881-7823) is an international peer-reviewed journal. BioScience Trends devotes to publishing the latest and most exciting advances in scientific research. Articles cover fields of life science such as biochemistry, molecular biology, clinical research, public health, medical care system, and social science in order to encourage cooperation and exchange among scientists and clinical researchers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信